The impact and role of EGFR gene mutation on non-small cell lung cancer

Shinichi Toyooka, Junichi Sou, Hisayuki Shigematsu, Motoi Aoe, Hiroshi Date

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.

Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume58
Issue numberSUPPL.
DOIs
Publication statusPublished - Nov 2006

Fingerprint

erbB-1 Genes
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Genes
Cells
Mutation
Epigenomics
Carcinogenesis
Adenocarcinoma
Assays
Translational Medical Research
Biomarkers
Exons
Lung Neoplasms
Lung

Keywords

  • EGFR
  • Erlotinib
  • Gefitinib
  • KRAS
  • Methylation
  • NSCLC

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

The impact and role of EGFR gene mutation on non-small cell lung cancer. / Toyooka, Shinichi; Sou, Junichi; Shigematsu, Hisayuki; Aoe, Motoi; Date, Hiroshi.

In: Cancer Chemotherapy and Pharmacology, Vol. 58, No. SUPPL., 11.2006.

Research output: Contribution to journalArticle

Toyooka, Shinichi ; Sou, Junichi ; Shigematsu, Hisayuki ; Aoe, Motoi ; Date, Hiroshi. / The impact and role of EGFR gene mutation on non-small cell lung cancer. In: Cancer Chemotherapy and Pharmacology. 2006 ; Vol. 58, No. SUPPL.
@article{bfd4569ed30c4a5980395a53629d6431,
title = "The impact and role of EGFR gene mutation on non-small cell lung cancer",
abstract = "Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.",
keywords = "EGFR, Erlotinib, Gefitinib, KRAS, Methylation, NSCLC",
author = "Shinichi Toyooka and Junichi Sou and Hisayuki Shigematsu and Motoi Aoe and Hiroshi Date",
year = "2006",
month = "11",
doi = "10.1007/s00280-006-0312-8",
language = "English",
volume = "58",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "SUPPL.",

}

TY - JOUR

T1 - The impact and role of EGFR gene mutation on non-small cell lung cancer

AU - Toyooka, Shinichi

AU - Sou, Junichi

AU - Shigematsu, Hisayuki

AU - Aoe, Motoi

AU - Date, Hiroshi

PY - 2006/11

Y1 - 2006/11

N2 - Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.

AB - Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.

KW - EGFR

KW - Erlotinib

KW - Gefitinib

KW - KRAS

KW - Methylation

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=33845235061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845235061&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0312-8

DO - 10.1007/s00280-006-0312-8

M3 - Article

AN - SCOPUS:33845235061

VL - 58

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - SUPPL.

ER -